Information on COVID-19 for patients taking Tremfya®▼ (guselkumab) Read More


  1. The National Psoriasis Foundation: Moderate to Severe Psoriasis and Psoriatic Arthritis: Biologic Drugs. Available at:
  2. Tremfya® Patient Information Leaflet. Available at: [Last accessed: April 2019].
  3. Griffiths C, & Barker J. Lancet. 2007;370(9583):263-271.
  4. Tremfya® Summary of Product Characteristics. Available at:[Last accessed: April 2019].
  5. Reich K, et al. J Am Acad Dermatol. 2017;76(3):418-431.
  6. NICE. TA521. 2018. Available at: [Last accessed: September 2018]
  7. Griffiths C, et al. Maintenance of response with guselkumab for up to 3 years’ treatment in the Phase 3 VOYAGE 1 trial of patients with plaque psoriasis. Falls Clinical Dermatology Conference, 18–12 Oct, 2018; Las Vegas, USA.
  8. The Psoriasis Association: Psoriasis & Treatments. Available at:
  9. WedMD: Talking about your psoriasis with others. Available at:
  10. Psoriasis speaks: Talking with family and friends. Available at:
  11. Crohn’s & Colitis UK. Employment & IDB: A guide for employees. Available at:
  12. Freedom 360: Psoriasis in the workplace. Available at:
  13. National Psoriasis Foundation: Psoriasis in the workplace. Available at:[Last accessed: October 2018]
  14. National Institute for Health and Care Excellence. Ustekinumab for treating active psoriatic arthritis. Clinical Guideline CG153; October 2012. Available at